Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Obesity Drugs Set to Become a Major Growth Engine for India’s Pharma Sector
Analysts say this shift toward high-value therapies backed by technology and regulatory support, could create new avenues for growth domestically and in export markets, reshaping the traditional pharma landscape that has long been dominated by generics.
- By Newsdesk
- New Delhi
- Dec 29, 2025
Obesity-focused medications, particularly the latest generation of treatments targeting metabolic disorders, are emerging as a promising growth catalyst for India’s pharmaceutical industry, industry leaders say.
Sun Pharmaceutical Industries’ Managing Director Kirti Ganorkar highlighted that expanding access to advanced obesity and diabetes drugs over the next few years could significantly accelerate domestic pharma growth. These therapies—especially GLP-1 receptor agonists, which regulate insulin and appetite—are increasingly viewed as essential tools in tackling lifestyle-related diseases such as obesity and type-2 diabetes.
“Broadening access to innovative treatments like GLP-1 agonists will be a key driver for the Indian pharmaceutical industry,” Ganorkar told PTI, noting that rising lifestyle disease burdens have heightened demand for such medicines.
Industry experts also believe that combining these novel drugs with AI-driven diagnostic tools and personalised care models can enhance early detection and patient outcomes, while supporting innovation that keeps treatments both affordable and accessible.
Sun Pharma isn’t alone in underscoring this trend. Other industry voices have stressed the importance of risk capital and research investment to help India evolve from a leading generic manufacturer into a global innovation hub in pharmaceuticals. Such efforts tie into broader national ambitions, including growing the sector into a $500 billion industry by 2047 and reinforcing India’s reputation as a reliable global healthcare partner.
The enthusiasm around obesity drugs also comes amid a broader transformation in the Indian market, where drugmakers are preparing for potential launches of locally manufactured versions of blockbuster obesity treatments as patents expire in 2026.
Analysts say this shift toward high-value therapies backed by technology and regulatory support, could create new avenues for growth domestically and in export markets, reshaping the traditional pharma landscape that has long been dominated by generics.